← Back to PRLD

Prelude Therapeutics Incorporated - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 11/08/2026Mar 2026Filed 11/08/2026Sep 2025Filed 12/11/2025Jun 2025Filed 11/08/2026Mar 2025Filed 11/08/2026Sep 2024Filed 12/11/2025Jun 2024Filed 12/11/2025Mar 2024Filed 12/11/2025
$5.7$4.6$6.5$0$0$3
−$14−$10−$20−$31−$32−$32−$35−$31
−$0.14−$0.13−$0.26−$0.41−$0.42−$0.43−$0.46−$0.42
9883767676767676

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.